These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9734695)

  • 1. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.
    Cheson BD
    Leuk Res; 1998 May; 22 Suppl 1():S17-21. PubMed ID: 9734695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan in the treatment of hematologic malignancies.
    Beran M; Kantarjian H
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
    Cheson BD; Jasperse DM; Simon R; Friedman MA
    J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
    Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
    Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
    Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
    Xu WL; Jin J; Qian WB
    Chin Med J (Engl); 2010 Jan; 123(1):108-10. PubMed ID: 20137586
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
    Chen YX; Ma XR; Zhang WG; Liu J; Cao XM; He AL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1002-5. PubMed ID: 18928583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
    Estey EH
    Oncology (Williston Park); 1998 Nov; 12(11A):81-6. PubMed ID: 10028504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
    Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
    Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of low-dose chemotherapy in myelodysplastic syndromes.
    Aul C; Gattermann N
    Leuk Res; 1992; 16(3):207-15. PubMed ID: 1560670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
    Ma XR; Wang J; Zhang WG; Chen YX; Cao XM; He AL; Liu J; Wang JL; Gu LF; Lei B; Zhang PY; Zhao WH; Yang Y; Wang FX; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):369-74. PubMed ID: 25948187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic agents for the treatment of myelodysplastic syndromes.
    Cheson BD; Zwiebel JA; Dancey J; Murgo A
    Semin Oncol; 2000 Oct; 27(5):560-77. PubMed ID: 11049023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylating agents and chemotherapy in MDS.
    Adès L; Santini V
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.